Share this
Digg
Del.icio.us
StumbleUpon
Netscape
Yahoo
Technorati
Googlize this
Facebook
Export PDF
Print
E-mail
Eli Lilly & Co. (LLY) will close its Singapore Center for Drug Discovery in December, a spokeswoman for the U.S. pharmaceutical group said Monday.
The spokeswoman said in an email response to queries from Dow Jones Newswires that the facility, which was a joint collaboration with the Singapore government’s Economic Development Board, will close “to ensure we are structured to most efficiently bring innovative new medicines to patients” and that “projects and capabilities deemed a priority for Lilly’s global research organization will be transitioned to the company’s global headquarters” in the U.S.
The spokeswoman said in an email response to queries from Dow Jones Newswires that the facility, which was a joint collaboration with the Singapore government’s Economic Development Board, will close “to ensure we are structured to most efficiently bring innovative new medicines to patients” and that “projects and capabilities deemed a priority for Lilly’s global research organization will be transitioned to the company’s global headquarters” in the U.S.
About 130 employees at the Singapore facility will be “impacted” by the decision, she said. Arrangements have been made for a limited number of management personnel to relocate to the company’s global headquarters.
The center was established as Lilly Systems Biology facility in 2002 and renamed Lilly Singapore Center for Drug Discovery following a second stage expansion.
